# Congenital Cytomegalovirus: Efficacy of Antiviral Treatment

> **NCT02005822** · PHASE3 · COMPLETED · sponsor: **Dr. Ann C.T.M. Vossen** · enrollment: 37 (actual)

## Conditions studied

- Congenital Cytomegalovirus Infection
- Sensorineural Hearing Loss

## Interventions

- **DRUG:** Valganciclovir

## Key facts

- **NCT ID:** NCT02005822
- **Lead sponsor:** Dr. Ann C.T.M. Vossen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-22
- **Primary completion:** 2018-05-17
- **Final completion:** 2018-05-17
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2021-06-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02005822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02005822, "Congenital Cytomegalovirus: Efficacy of Antiviral Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02005822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*